Profund Advisors LLC reduced its position in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 7.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 7,202 shares of the biopharmaceutical company’s stock after selling 598 shares during the period. Profund Advisors LLC’s holdings in Intercept Pharmaceuticals were worth $815,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the stock. OMERS ADMINISTRATION Corp raised its stake in shares of Intercept Pharmaceuticals by 18.2% in the third quarter. OMERS ADMINISTRATION Corp now owns 3,900 shares of the biopharmaceutical company’s stock worth $642,000 after buying an additional 600 shares during the last quarter. Polar Capital LLP raised its stake in shares of Intercept Pharmaceuticals by 5.2% in the third quarter. Polar Capital LLP now owns 23,000 shares of the biopharmaceutical company’s stock worth $3,786,000 after buying an additional 1,131 shares during the last quarter. EULAV Asset Management raised its stake in shares of Intercept Pharmaceuticals by 17.9% in the third quarter. EULAV Asset Management now owns 46,000 shares of the biopharmaceutical company’s stock worth $7,571,000 after buying an additional 7,000 shares during the last quarter. BOKF NA bought a new stake in shares of Intercept Pharmaceuticals during the third quarter worth $1,820,000. Finally, Pacer Advisors Inc. raised its stake in shares of Intercept Pharmaceuticals by 9.5% in the third quarter. Pacer Advisors Inc. now owns 1,384 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 82.28% of the company’s stock.
Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) opened at 112.27 on Friday. Intercept Pharmaceuticals Inc has a one year low of $96.63 and a one year high of $177.93. The stock’s market capitalization is $2.81 billion. The firm’s 50-day moving average is $112.38 and its 200-day moving average is $112.96.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The company had revenue of $21 million during the quarter, compared to analyst estimates of $15.88 million. During the same period last year, the firm posted ($5.17) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 4566.7% compared to the same quarter last year. On average, analysts expect that Intercept Pharmaceuticals Inc will post ($14.65) earnings per share for the current fiscal year.
ICPT has been the topic of a number of research reports. Wedbush reaffirmed an “outperform” rating and set a $224.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, February 8th. Cantor Fitzgerald reissued an “underweight” rating and set a $60.00 price objective on shares of Intercept Pharmaceuticals in a research note on Monday, February 13th. Laidlaw raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 price objective on the stock in a research note on Friday, May 5th. Oppenheimer Holdings Inc. set a $200.00 price objective on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, February 11th. Finally, Robert W. Baird reissued an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a research note on Thursday, February 16th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $188.37.
In other Intercept Pharmaceuticals news, CMO David Shapiro sold 1,117 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $112.18, for a total transaction of $125,305.06. Following the completion of the transaction, the chief marketing officer now directly owns 46,582 shares of the company’s stock, valued at approximately $5,225,568.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lisa Bright sold 426 shares of the firm’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was sold at an average price of $114.00, for a total transaction of $48,564.00. Following the transaction, the insider now directly owns 23,804 shares of the company’s stock, valued at $2,713,656. The disclosure for this sale can be found here. Insiders have sold a total of 3,318 shares of company stock valued at $375,832 over the last three months. 9.20% of the stock is currently owned by insiders.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.